Proactiveinvestors RSS feed en Sat, 18 Aug 2018 12:45:58 +1000 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - Board Change ]]> Fri, 10 Aug 2018 16:00:04 +1000 <![CDATA[RNS press release - Agreement ]]> Thu, 09 Aug 2018 16:00:07 +1000 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> Wed, 25 Jul 2018 23:45:48 +1000 <![CDATA[RNS press release - Issue of Equity ]]> Tue, 24 Jul 2018 16:00:10 +1000 <![CDATA[RNS press release - Scancell exercises TriGrid commercial option ]]> Wed, 18 Jul 2018 16:00:03 +1000 <![CDATA[News - Scancell Holdings inks drug delivery technology deal ]]> Immunotherapy specialist Scancell Holdings PLC (LON:SCLP) has exercised an option to in-licence delivery technology for its lead drug candidate.

It has inked a deal with Ichor Medical Systems, which has developed the TriGrid 2.0 electroporation system.

READ: Scancell receives European patent protection for immunotherapy platform

TriGrid will now be used in harness with Scancell's SCIB1 vaccine, a melanoma treatment.

Specifically, it will be deployed in an upcoming Phase II clinical trial in which the Scancell drug candidate is being deployed alongside a checkpoint inhibitor.

Vital component 

Chief executive Cliff Holloway said: "Ichor's proprietary TriGrid electroporation delivery system is a vital component for the delivery of our SCIB1 vaccine and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, which is expected to commence later this year.

“The exercise of this commercial option is a further key milestone in bringing this important new treatment to the market."

The company said an option fee will be paid. Ichor will receive further cash once certain developmental milestones are passed.

Scancell has also agreed an extension for the exercise of share options granted to Ichor as part of the initial deal.

Wed, 18 Jul 2018 08:09:00 +1000
<![CDATA[RNS press release - Grant of European patent for Moditope platform ]]> Wed, 23 May 2018 16:00:12 +1000 <![CDATA[News - Scancell receives European patent protection for immunotherapy platform ]]> Scancell Holdings PLC (LON:SCLP) said the European Patent Office has "granted broad protection" for the company's Moditope immunotherapy platform, which comes into effect from June 13.

It covers the company's pipeline of Moditope-derived vaccines. Counterparts to the patent have been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US, the firm added.

"This is a key patent for Scancell and endorses our work in identifying a new class of cancer vaccine capable of inducing potent immune responses to stress-induced post-translational modifications (siPTM), in this case, through citrullination of cellular proteins," said chief scietific officer,  Professor Lindy Durrant.

Well positioned

"We are now well positioned to develop a pipeline of new Moditope therapies with the potential to address the unmet need across a broad range of hard-to-treat cancers including ovarian, triple negative breast cancer and sarcoma."

First-in-man trials with Modi-1, which combines Moditope peptides with an ultra-efficient substance called an adjuvant that enhances the body's immune response, are due to start in the first half of next year.


Wed, 23 May 2018 07:28:00 +1000
<![CDATA[RNS press release - Holding(s) in Company ]]> Fri, 11 May 2018 22:11:00 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Wed, 09 May 2018 19:12:18 +1000 <![CDATA[RNS press release - Result of the Open Offer and PDMR Shareholdings ]]> Tue, 08 May 2018 16:00:09 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Mon, 23 Apr 2018 21:43:04 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Sat, 21 Apr 2018 01:32:41 +1000 <![CDATA[RNS press release - Result of Placing and Subscription and PDMR ]]> Wed, 18 Apr 2018 23:29:00 +1000 <![CDATA[RNS press release - Second Price Monitoring Extn ]]> Wed, 18 Apr 2018 20:05:28 +1000 <![CDATA[RNS press release - Price Monitoring Extension ]]> Wed, 18 Apr 2018 20:00:15 +1000 <![CDATA[RNS press release - Technology acquired from University of Nottingham ]]> Wed, 18 Apr 2018 16:00:05 +1000 <![CDATA[Media files - Scancell to raise up to £8mln to develop its three main drug candidates ]]> Wed, 18 Apr 2018 14:18:00 +1000 <![CDATA[News - Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs ]]> Immunotherapy specialist Scancell Holdings Plc (LONSCLP) has raised £6.9mln net of expenses in a discounted placing and share subscription, with the cash to be used develop its three main drug candidates.

The stock was sold to investors at 14p, 31% below last's night's close.

WATCH: Scancell to raise up to £8mln to develop its three main drug candidates

The combined proceeds will be used to fund a phase II trial of the company’s lead drug, SCIB-1, in combination with a checkpoint inhibitor to treat late-stage melanoma.

Cancer Research UK 

Cash will also be deployed to support the Cancer Research UK development of SCIB2 for non-small-cell lung cancer.

And it will be used to begin a first-in-human study of Modi-1 in patients with triple-negative breast cancer, ovarian cancer and sarcoma planned to start in the first-half of next year.

In a separate announcement, Scancell said it had acquired a number of unique monoclonal antibodies to tumour-associated glycans that have the potential, when coupled with a method of activating the immune system, to provide a new class of cancer immunotherapy.

“We believe this platform complements our existing ImmunoBody and Moditope platforms, significantly broadening the strength and potential of Scancell's immunotherapy pipeline," said chief executive Cliff Holloway.

 -- Updates with placing completion details, share price --

Wed, 18 Apr 2018 08:00:00 +1000
<![CDATA[RNS press release - Manufacturing agreement with The PolyPeptide Group ]]> Tue, 03 Apr 2018 16:00:11 +1000 <![CDATA[News - Scancell signs manufacturing agreement for its Moditope anti-cancer platform ]]> Scancell Holdings Plc (LON:SCLP) has signed an agreement with The PolyPeptide Group for the manufacture of its first Moditope anti-cancer platform, Modi-1-AMPLIVANT.

The AIM-listed firm said that the contract with the independent contract manufacturer of therapeutic peptides was signed at the end of March 2018.

READ: Scancell to work with Dutch firm on first on first product for Moditope cancer immune-therapy platform

The cancer specialist said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Scancell said it plans to commence a phase I/II clinical trial of Modi-1-AMPLIVANT in the first half of 2019 in patients with triple-negative breast cancer, ovarian cancer and sarcomas.

Cliff Holloway, CEO of Scancell, said: “Commencing GMP manufacture is an important step in the development of our first Moditope product and is key to moving this novel therapy into the clinic in the first half of 2019.”

Tue, 03 Apr 2018 07:40:00 +1000
<![CDATA[RNS press release - Scancell to present at the Calculus Investor Forum ]]> Fri, 16 Feb 2018 22:30:01 +1100 <![CDATA[RNS press release - Hardman Res. - Validating multiple opportunities ]]> Thu, 15 Feb 2018 18:15:01 +1100 <![CDATA[RNS press release - Collaboration agreement with ISA Pharmaceuticals ]]> Thu, 15 Feb 2018 18:00:04 +1100 <![CDATA[Media files - New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments ]]> Thu, 15 Feb 2018 12:38:00 +1100 <![CDATA[News - Scancell to work with Dutch firm on first product for Moditope cancer immuno-therapy platform ]]> Scancell Holdings PLC (LON:SCLP) saw its shares advance today after the firm agreed another collaborative development for its Moditope anti-cancer platform.

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform. Eventually, the collaboration might offer new treatments for triple negative breast cancer, ovarian, sarcomas and other solid tumours.

WATCH: New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments

Scancell will make an (undisclosed) upfront payment in return for an exclusive worldwide licence to manufacture, develop and commercialise Amplivant:Modi-1.

Clinical studies are scheduled to start in the first half of 2019.

Moditope is an immunotherapy agent that acts to stimulate the production of killer CD4+ T cells, the body’s own defence against tumours.

Amplivant enables lower doses and improves efficacy by enabling the body to better recognise cancerous cells and attack them with T cells.

Cliff Holloway, Scancell’s chief executive, said working with ISA was an important first step towards commercialising the Moditope immunotherapy, Modi-1.

READ: Scancell to receive patent protection for key cancer platform

“Our pre-clinical studies have demonstrated Modi-1 induces potent anti-tumour responses and significant improvements in survival”.

“We believe that combining Modi-1 with an enabling adjuvant technology such as Amplivant has the potential to significantly enhance its efficacy in patients.”

Ronald Loggers, ISA’s chief executive, added: "The partnership will further validate the power of Amplivant conjugates for use in therapeutic cancer vaccines."

Last year, Scancell agreed a Moditope collaboration with another European firm, BioNTech for high-throughput cloning and characterisation of naturally selected T-cell receptors.

In late afternoon trading, Scancell shares were up 12% at 140.

 -- Adds share price --

Thu, 15 Feb 2018 08:00:00 +1100
<![CDATA[RNS press release - Publication highlights potential of SCIB1 therapy ]]> Mon, 12 Feb 2018 18:00:03 +1100 <![CDATA[News - Scancell drug receives positive write-up in leading journal as company updates on survival data ]]> The cancer specialist Scancell Holdings PLC’s (LON:SCLP) said its lead drug has received a glowing write-up in a leading cancer journal as it released data from melanoma patients five years on from receiving the treatment.

Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology.

It assessed the data from Scancell’s Phase I/II study of patients with late-stage melanoma, which had been operated on and received five doses of SCIB 1.

READ: Our Big Picture article on Scancell 

The authors concluded SCIB1 was “worthy of further study” particularly in an “adjuvant setting”. An adjuvant enhances the drug’s response.

Importantly, the researchers thought there may be a role for the drug to be used in combination with drugs called checkpoint inhibitors in the late stages of the disease (which will be the focus of the next trial).

An extract from the paper appears below:

SCIB1 is a novel class of anti-cancer immunotherapy that induces T cells which can cause tumour regression in patients with melanoma. The high frequency of responses, their breadth and durability suggest that SCIB1 is worthy of further study in a larger cohort of patients. This is particularly the case in the adjuvant setting, where all of the patients responded immunologically and where absence of toxicity is an important clinical consideration. Furthermore, the stimulation of potent de novo immune responses by SCIB1 may provide an opportunity for synergistic combination therapy with checkpoint inhibitors in late stage disease.

On Monday, the company also updated on those who received the therapy in that early trial, with 18 of 20 stage III/IV melanoma sufferers still alive.

Of the 16 who received 2-4 mg doses of SCIB1, only six patients have had recurrence of their disease, with only two deaths.

All 14 surviving patients in this group have passed the five year time point since study entry. 

The four patients who had disease recurrence went on to receive other treatments for their melanoma. The other 10, who had received multiple different drugs before entering the trial, had no treatment other than SCIB1.

Impressive survival data 

“The continuing survival of these patients is impressive as many had undergone multiple resections of their tumours prior to SCIB1 treatment but have had no evidence of any further disease recurrence,” said Scancell chief executive, Dr Cliff Holloway.

“This compares extremely favourably with checkpoint inhibitors, but has the advantage of being associated with significantly less toxicity.

“We remain on track to submit an IND to enable our phase II study combining SCIB1 with a checkpoint inhibitor to start in the second half of this year."

As mentioned above, the Phase II study of SCIB1 is expected to get underway in the second half of 2018 following the completion of all the pre-trial formalities and submissions.

Combination therapy

The drug will be tested in combination with a checkpoint inhibitor and the programme will be overseen by Dr Keith Flaherty, a director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital and an Associate Professor at Harvard Medical School. 

He said: "Although the checkpoint inhibitors have improved the prognosis for many melanoma patients, a significant proportion of patients do not respond to these new regimes. 

“The combination of SCIB1 with a checkpoint inhibitor may significantly expand the population of patients who benefit from immunotherapy."

The shares, up 36% in the last week, rose a further 3.6% in morning trade to 13.68p.

---adds share price---

Mon, 12 Feb 2018 08:01:00 +1100
<![CDATA[RNS press release - European patent application allowed for grant ]]> Fri, 09 Feb 2018 18:00:03 +1100 <![CDATA[News - Scancell to receive patent protection for key cancer platform ]]> Scancell Holdings Plc (LON:SCLP) said the European Patent Office intends to grant the company’s patent application for the Moditope immunotherapy platform.

Once formally granted the patent will provide protection for Scancell’s pipeline of Moditope vaccines that could help revolutionise the way cancer is treated.

READ: Scancell-led team short-listed for award

The patent will cover all major areas in Europe, while similar filings have been made in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate,” said chief executive Cliff Holloway. 

“This is a key case for the company as we progress development of our Moditope platform and provides further protection for Scancell's innovative cancer vaccine technologies."

Fri, 09 Feb 2018 07:30:00 +1100
<![CDATA[RNS press release - Scancell member of team shortlisted for CRUK award ]]> Thu, 08 Feb 2018 18:00:06 +1100 <![CDATA[News - Scancell-led team short-listed for award ]]> A team led by Scancell Holdings Plc’s (LON:SCLP) chief scientific officer that is pioneering a vaccine-led approach to tackling tumours has been shortlisted for  a £20mln award.

Professor Lindy Durrant is teaming up with researchers from Genentech, BioNtech and ISA Pharmaceuticals to develop Project Blueprint.

The scientists are aiming to identify the most effective treatments for patients with most strains of the disease.

However the focus, at least initially, will be on head, neck lung, and pancreatic cancers as well as, glioblastoma - all of which currently have a poor prognosis.

Modi-3 may play a role

As part of the programme, Durrant’s team will consider whether Scancell’s Modi-3 product has a role to play.

Project Blueprint has been shortlisted for the Cancer Research UK Grand Challenge, a prestigious award that brings with it £20mln of funding.

Last year four teams won financial backing from the charity.

READ: Scancell eyeing investigational new drug application for SCIB1 in first half

Durrant said: “This brings us one step closer to delivering our cancer vaccine blueprint. 

“We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. 

“Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

Thu, 08 Feb 2018 08:00:00 +1100
<![CDATA[RNS press release - Director/PDMR Shareholding ]]> Thu, 01 Feb 2018 18:00:13 +1100 <![CDATA[RNS press release - Half-year Report ]]> Tue, 30 Jan 2018 18:00:03 +1100 <![CDATA[News - Scancell eyeing investigational new drug application for SCIB1 in first half ]]> Scancell Holdings Plc (LON:SCLP) expects to submit an investigational new drug (IND) application for its SCIB1 skin cancer drug candidate in the first half of 2018.

The immune-oncology specialist said in its interim results statement that patient enrolment for the SCIB1 Phase 2 checkpoint inhibitor combination study for patients with advanced melanoma is planned to start in the second half of the year, subject to receiving sufficient funding.

READ: Scancell poised for “significant” year with its immuno-oncology portfolio

Following the pre-IND meeting in 2017, the US Food and Drug Administration (FDA) suggested that technical data from Ichor's new TriGrid 2.0 clinical device should be submitted 30-60 days prior to Scancell's own FDA submission; Ichor expects to make its Master File submission any week now.

Scancell is also close to initiating GMP (good manufacturing practice) manufacture of Modi-1, the lead product from its Moditope platform, for the planned Phase 1/2 clinical trial in triple negative breast cancer, ovarian cancer and sarcoma, which is planned to start in the first half of 2019 and will continue to advance Modi-2 in preparation for clinical trials in other solid tumours resistant to checkpoint inhibitor therapy.

READ: Scancell Holdings raises £5mln as the pace of clinical work quickens

Financial results for the six months to the end of October showed losses widened slightly to £2.02mln from £1.72mln the year before, as development expenditure increased.

The group also saw an increase in administrative expenditure, largely due to a significant increase in patent costs as the company continues to protect and extend its intellectual property portfolio.

Scancell ended the reporting period with a cash balance of £5.0mln, up from £2.7mln at the beginning of the period, after it raised £4.7mln through a placing of shares in May.

READ: Scancell inks research collaboration deal with European biopharma BioNTech

"Our lead ImmunoBody, SCIB1, continues to demonstrate remarkable survival data,” said Dr Cliff Holloway, Scancell’s newly installed chief executive officer.

Referring to the group’s recently signed collaboration deals with BioNTech and Cancer Research UK, Holloway said the deals provided the first external validation of Scancell’s ImmunoBody and Moditope immunotherapy platforms.

READ: Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial

“Cancer Research UK's world-renowned expertise will be invaluable as SCIB2 is progressed into Phase 1/2 clinical trials, and we are excited to be working with BioNTech in one of the most promising areas of cancer immunotherapy: the development of T cell receptor therapeutics,” Holloway said.

Tue, 30 Jan 2018 07:58:00 +1100
<![CDATA[Media files - Scancell research collaboration deal with European biopharma BioNTech ]]> Fri, 12 Jan 2018 12:13:00 +1100 <![CDATA[RNS press release - Scancell to collaborate with BioNTech ]]> Tue, 09 Jan 2018 18:00:02 +1100 <![CDATA[News - Scancell inks research collaboration deal with European biopharma BioNTech ]]> Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer.

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T-cell receptors.

READ: Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial

Moditope is a new class of potentially potent immunotherapy agents which stimulate the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

To get a bit scientific, Moditope stimulates the production of the CD4+ T cells using tumour-associated peptide epitopes which allow the activated T cells to seek out and kill tumour cells that would otherwise have been hidden from the immune system.

Once the initial studies have been completed, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Scancell’s Modi-1 epitopes.

‘Great potential’

“We are delighted to be working with BioNTech, one of Europe's new immuno-oncology power-houses, to investigate the development of targeted immunotherapies for the treatment of cancer,” Scancell’s chief scientific officer Lindy Durrant.

READ: Scancell on the lookout for partners after year of “significant progress”

“Pre-clinical data from our Moditope platform has shown unprecedented anti-tumour effects can be delivered without the need for checkpoint inhibition.

“We believe that this, combined with BioNTech's engineered T cells specific to Moditope epitopes, could have great potential as a novel immunotherapy.”

Tue, 09 Jan 2018 07:51:00 +1100
<![CDATA[RNS press release - Scancell and CRUK to advance cancer immunotherapy ]]> Thu, 14 Dec 2017 18:00:03 +1100 <![CDATA[Media files - Cancer Research UK collaboration 'a stunning endorsement' for Scancell ]]> Thu, 14 Dec 2017 13:21:00 +1100 <![CDATA[News - Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial ]]> Shares in Scancell Holdings PLC (LON:SCLP) soared on Thursday morning after the company revealed Cancer Research UK is to fund and sponsor a Phase I/II clinical trial of its SCIB2 lung cancer vaccine.

Scancell said the tie-up was a “significant endorsement” of its ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 which helps to prime a patient’s immune system to recognise and kill specific cancer cells.

Cancer Research to manage the trial

The study that Cancer Research UK – one of the world’s leading cancer charities – is to pay for will see patients with solid lung cancer tumours treated in combination with a checkpoint inhibitor.

The charity’s Centre for Drug Development will be responsible for manufacturing the clinical trial supplies of SCIB2, conducting the pre-clinical testing, as well as sponsoring and managing the trial itself.

Once the study has been completed, Scancell will have the option to acquire the rights to the data to support the further development of SCIB2 itself.

If Scancell decides not to do this, Cancer Research will retain the right to take the programme forward in all indications, not just lung cancer.

Scancell CSO “delighted”

“The charity's world-renowned expertise will no doubt be invaluable as we progress SCIB2 through the clinic,” said chief scientific officer Lindy Durrant.

“In pre-clinical studies, we have shown that a combination of SCIB2 and checkpoint inhibition produces enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

“We believe SCIB2 has the potential to provide a much needed treatment option for patients suffering from a range of common solid tumours.”

Shares jumped 14% to 14.3p on Thursday morning.

--Updates for share price--

Thu, 14 Dec 2017 11:06:00 +1100
<![CDATA[RNS press release - Result of AGM ]]> Wed, 11 Oct 2017 19:44:37 +1100 <![CDATA[RNS press release - Directorate Change ]]> Tue, 10 Oct 2017 17:00:04 +1100 <![CDATA[News - Scancell recruits deal maker to take over as CEO ]]> Scancell Holdings PLC (LON:SCLP) has nabbed Dr Cliff Holloway from Benitec Biopharma to be its new chief executive officer, succeeding Dr Richard Goodfellow.

Goodfellow will remain on the board of directors.

READ: Scancell on the lookout for partners after year of “significant progress”

Holloway will seek to drive progress of Scancell's immunotherapy platforms ImmunoBody and Moditope and oversee their commercialisation, the company said.

Holloway was previously chief business and operating officer at Benitec, and before that was chief executive officer of Sienna Cancer Diagnostics.

John Chiplin, executive chairman of Scancell, paid tribute to Goodfellow, saying if it wasn't for his significant achievements, Scancell would not be in the position it's in today.

“We are about to embark on a Phase 2 checkpoint inhibitor combination study with our ImmunoBody vaccine, SCIB1, in melanoma; and our lead Moditope, Modi-1, is progressing rapidly towards the clinic. I would like to thank Richard wholeheartedly for his hard work and substantial contribution to the business, and look forward to continue working alongside him on the board of directors,” Chiplin said.

READ: Scancell presents Moditope data at prestigious cancer conference

Dr Goodfellow said the appointment of Dr Holloway would ensure that Scancell has “a leader with the right mix of skills to guide the company into its next phase of growth”.

“Cliff is an experienced deal maker, which combined with his deep understanding of the science makes him an ideal choice for the job. I have known Cliff for over 10 years and very much look forward to supporting him in his new position," Dr Goodfellow said.

Shares in Scancell were down 1.1% at 12.36p in early deals.

Tue, 10 Oct 2017 08:54:00 +1100
<![CDATA[RNS press release - Notice of AGM ]]> Thu, 14 Sep 2017 16:00:07 +1000 <![CDATA[RNS press release - Final Results ]]> Wed, 13 Sep 2017 16:00:04 +1000 <![CDATA[News - Scancell on the lookout for partners after year of “significant progress” ]]> Cancer-focused immunotherapy developer Scancell Holdings Plc (LON:SCLP) is looking to bring on board one or more partners to help take its ImmunoBody and Moditope platforms to the next stage.

As of 30 April, the company had £2.7mln in the bank and it expects the coffers to need topping up as it prepares for a phase II trial of its SCIB1 skin cancer treatment over in the US.

“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase,” said chief executive Richard Goodfellow.

“The board believes that this funding could be best achieved following the execution of one or more partnerships on the ImmunoBody or Moditope platforms, on which significant progress has been made since the year end.”

Both platforms advancing

Scancell also told investors that it has made “significant progress” over the past year or so.

SCIB1 continues to produce “strong survival data” from its phase I/II clinical trial and compares favourably with ipilimumab – the current stand of care for late-stage melanoma patients – which has previously received approval in the US, Canada and the EU.

READ: SCIB1 continues to produce strong survival data

An investigational new drug (IND) application to the US Food and Drug Administration for a phase II study is expected to be submitted early next year, with patient enrolment planned also planned for 2018.

Modi-1 – the lead product from the Moditope platform – has also made “continued good progress” and Scancell said it is aiming to file a Clinical Trial Application (CTA) in the UK for the planned phase I/II  clinical trial in breast cancer, ovarian cancer and sarcoma in 2018.

Boss hails ‘further significant progress’

“We have made further significant progress during the course of the past year on the development of our ImmunoBody and Moditope platforms,” said Goodfellow.

“We continue to report strong survival data in patients with Stage III/IV melanoma from our SCIB1 Phase I/II clinical trial, with survival times now exceeding five years in resected patients.”

He added: “Moditope is also progressing well with the identification of a new linked adjuvant for the first Modi-1 clinical trial in the UK in patients with breast cancer, ovarian cancer and sarcoma which is expected to increase the potency of the product up to 100-fold.”

For the year to 30 April, Scancell reported a loss of £3.5mln (2016: Loss of £2.6mln).

Since the end of the period, Scancell successfully raised £4.7mln through a share placing, with the funds to be used in the clinical development of Modi-1 and support the ImmunoBody platform pipeline.

The company has also been granted a European patent for tis DNA ImmunoBody technology, with similar awards in the US, Australia and Japan.

Scancell shares were down 8.8% to 12.68p in early deals on Wednesday.

--Updates for share price--

Wed, 13 Sep 2017 08:21:00 +1000
<![CDATA[RNS press release - Presents Moditope Data at Immunotherapy Conference ]]> Mon, 11 Sep 2017 16:00:06 +1000 <![CDATA[News - Scancell presents Moditope data at prestigious cancer conference ]]> Cancer drug developer Scancell Holdings PLC (LON:SCLP) presented the latest data from its Moditope platform at the International Cancer Immunotherapy conference in Germany – one of the most prestigious meetings in the industry’s calendar.

Moditope stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

The AIM-quoted firm’s chief scientific officer Lindy Durrant presented two posters at the conference on Friday.

LOOK: Take a look at the two posters

The data showed that Modi-1 – the lead product from the platform – induced strong anti-tumour immunity in pancreatic, lung, ovarian and melanoma cancer models with up to 100% survival.

“Our poster in collaboration with ISA Pharmaceuticals showed that Modi-1 conjugated to synthetic TLR1/2 agonists generated an anti-tumour response at up to 100-fold lower doses than Modi-1 alone and that these conjugated peptides induced a memory response against tumour re-challenge,” said Durrant.

“These results suggest that Modi-1 conjugated directly to TLR agonists could be a powerful new approach to the treatment of cancer.”

Shares rose 0.9% to 14.12p.

Mon, 11 Sep 2017 11:25:00 +1000
<![CDATA[RNS press release - Oncimmune and Scancell Present Autoantibodies Data ]]> Tue, 29 Aug 2017 16:00:08 +1000